#Saudi Arabia #Riyadh #Clinical Trials #Cellenkos #Princess Nourah

Advancing Clinical Research: A New Era of Collaboration

In a landmark agreement, the College of Medicine at Princess Nourah bint Abdulrahman University (PNU) has entered into a Memorandum of Understanding (MoU) with Cellenkos, Inc., a clinical-stage biotechnology firm. This partnership aims to foster collaboration in various domains including clinical trials, cell and gene therapies, and biomanufacturing technologies, marking a significant step towards advancing medical research and education in Saudi Arabia.

The Key Players in the Agreement

The signing ceremony was graced by notable figures such as Dr. Reem AlHarbi, the Dean of the College of Medicine at PNU, and Ms. Tara Sadeghi, the Chief Operating Officer of Cellenkos, Inc. The MoU signifies a mutual commitment to enhance educational quality and research capabilities in clinical trials and related fields. This partnership not only aligns with both parties' objectives to prepare qualified professionals but also emphasizes the importance of international collaboration in scientific research and education.

Expanding Educational Opportunities

As part of the collaboration, a wide array of programs is set to be developed. These will include curriculum design aimed at incorporating cutting-edge practices in clinical trials. Moreover, the initiative will provide a training program enriched with virtual sessions and live workshops focused on practical and research skills. This innovative approach is expected to create a dynamic learning environment for students pursuing careers in the healthcare and biotechnology sectors.

Promoting Scientific Research

The MoU emphasizes the importance of training students in scientific research, thereby contributing to the overall growth of the biotechnology landscape in the region. The College of Medicine will leverage Cellenkos’ expertise in cell and gene therapies to structure its training modules effectively. This initiative seeks to produce a fresh wave of professionals equipped with the necessary skills to tackle contemporary health challenges using biotechnological advances.

Government Support

Cellenkos has received recognition and support from the Ministry of Investment, Saudi Arabia (MISA) for this initiative, indicating the government’s commitment to fostering advancements in biomedicine and technology in the region. The MoU was formalized during the Riyadh Global Medical Biotechnology Summit (RGMBS), which is well-known for highlighting significant achievements in the medical biotechnology field.

Looking Ahead

As a first step, the partners plan to conduct an inaugural workshop in the first quarter of 2027. This event will serve as a foundation for subsequent engagements and will aim to involve a broader audience from the academic and healthcare communities. The partnership anticipates that it will pave the way for future collaborations aimed at enhancing medical exploration and treatment methodologies.

About Cellenkos, Inc.

Cellenkos, Inc. specializes in developing innovative therapies utilizing allogeneic tissue-directed, cord blood-derived T-regulatory cells, targeting autoimmune, neurodegenerative, and inflammatory diseases. Their commitment to advancing stem cell research and its applications has positioned them as leaders in their field.

About Princess Nourah bint Abdulrahman University

Established in 1970, PNU is the largest public women’s university worldwide, offering diverse programs from diplomas to postgraduate degrees across its 34 colleges. It has earned recognition for its emphasis on empowering women through education and research, contributing significantly to the academic landscape in Saudi Arabia.

The partnership between Princess Nourah bint Abdulrahman University and Cellenkos, Inc. not only signifies a growth opportunity for both institutions but also heralds a new chapter in enhancing healthcare delivery through research and education in the region.